Child Prodigy Targets Immortality With AI After PhD at 15

Laurent Simons, the Belgian prodigy who completed high school at age 8 and earned a quantum physics doctorate at 15, has announced his next mission: using artificial intelligence to crack the code of human aging and potentially achieve biological immortality. In his own words, death is simply 'a puzzle that hasn't been finished yet.'

Within hours of defending his doctoral thesis, Simons skipped the celebrations and boarded a flight with his father back to Munich, Germany — where he plans to begin his second PhD, this time at the intersection of AI and longevity science.

Key Facts at a Glance

• Age 4: Started primary school; completed all coursework by age 6
• Age 8: Finished high school, completing the entire K-12 curriculum
• Age 9: Enrolled in electrical engineering at Eindhoven University of Technology
• Age 12: Earned a master's degree in quantum physics from the University of Antwerp
• Age 15: Completed a PhD in quantum physics, focusing on quantum coherence and decoherence mechanisms
• Next step: A second doctorate applying AI to solve human aging

From K-12 at Age 8 to Quantum Physics PhD at 15

Simons' academic trajectory reads like science fiction. Born in Belgium, he entered primary school at age 4 and blazed through the entire curriculum in just 2 years. By the time his peers were starting third grade, he had already graduated from high school.

At 9 years old, Simons enrolled at the Eindhoven University of Technology in the Netherlands to study electrical engineering. His original plan was to compress a 3-year bachelor's program into just 10 months. However, a disagreement with the university over his graduation timeline led him to transfer to the University of Antwerp in Belgium, where he pivoted to physics.

The 3-year bachelor's program took him just 18 months. By age 12, he held a master's degree in quantum physics. His doctoral research tackled one of the most challenging areas in the field: quantum coherence and decoherence mechanisms — the study of how quantum states maintain or lose their quantum properties, a foundational problem for quantum computing and quantum information science.

At 15, he successfully defended his PhD thesis, making him one of the youngest doctoral graduates in recorded history.

Why AI Plus Longevity? Simons' Bold New Direction

Rather than resting on his extraordinary accomplishments, Simons has set his sights on what may be the most ambitious scientific challenge of the 21st century: defeating biological aging. His approach centers on leveraging artificial intelligence to decode the complex mechanisms that cause cells to deteriorate over time.

This pivot from quantum physics to AI-driven longevity research is less surprising than it might appear. The computational foundations of quantum mechanics share deep mathematical structures with modern machine learning. Simons' background in quantum coherence gives him unique insight into modeling complex systems — a skill directly transferable to biological modeling.

The AI longevity sector has exploded in recent years. Companies like Insilico Medicine, which raised $95 million in Series D funding, and Google's Isomorphic Labs are already deploying deep learning models to identify anti-aging drug candidates. Altos Labs, backed by $3 billion in funding from investors including Jeff Bezos and Yuri Milner, is using AI-assisted cellular reprogramming to reverse biological aging at the cellular level.

Simons entering this space adds a uniquely multidisciplinary perspective — one that bridges quantum-level understanding of molecular behavior with cutting-edge AI techniques.

The AI Longevity Landscape: A Booming Field

Simons is joining a research domain that has attracted billions of dollars in investment and some of the sharpest minds in technology and science. The convergence of AI and aging research represents one of the fastest-growing intersections in biotech.

Key players and developments in the space include:

• Altos Labs: Founded in 2022 with $3 billion, focused on cellular rejuvenation using Yamanaka factors and AI-guided research
• Insilico Medicine: Uses generative AI to discover novel anti-aging compounds; its AI-designed drug ISM001-055 entered Phase 2 clinical trials
• Calico Labs (Alphabet/Google): Applies machine learning to understand the biology of lifespan
• Isomorphic Labs (Google DeepMind spin-off): Leverages AlphaFold-derived protein structure prediction for drug discovery
• Retro Biosciences: Backed by $180 million from Sam Altman, aims to add 10 years to healthy human lifespan

The global anti-aging market is projected to reach $93 billion by 2027, according to Allied Market Research. AI is increasingly central to this growth, enabling researchers to simulate decades of cellular aging in hours and identify intervention targets that would take traditional methods years to discover.

What Makes Simons' Approach Different?

While many AI longevity researchers come from computer science or biology backgrounds, Simons brings a rare foundation in quantum physics. This distinction matters because the molecular processes underlying aging — DNA damage repair, protein folding errors, mitochondrial dysfunction — operate at scales where quantum effects become relevant.

Recent research published in journals like Physical Review Letters and Nature Physics has shown that quantum tunneling plays a role in DNA mutations, and quantum coherence may influence enzyme catalysis in cellular repair mechanisms. A researcher who understands both quantum mechanics at the doctoral level and modern AI architectures is uniquely positioned to bridge these domains.

Simons has not yet disclosed the specific university or research group he will join for his second PhD. However, Munich is home to several world-class institutions working at the intersection of AI and life sciences, including the Technical University of Munich (TUM) and the Ludwig Maximilian University, both of which have strong AI and computational biology programs. Munich is also home to the Helmholtz Center, one of Europe's largest biomedical research organizations.

The Ethics and Skepticism Around 'Solving Death'

Simons' framing of death as an 'unfinished puzzle' is inspiring to many but also raises significant questions. The longevity research community remains divided on whether biological immortality is achievable — or even desirable.

Critics point to several concerns:

• Overpopulation and resource strain if human lifespans extend dramatically
• Inequality of access: Life extension technologies could become exclusive to the ultra-wealthy
• Biological complexity: Aging involves hundreds of interconnected pathways that may resist simple AI-driven solutions
• Ethical boundaries: Questions about whether radically extending life alters what it means to be human

Supporters counter that even partial success — extending healthy lifespan by 10-20 years — would be transformative. AI models like AlphaFold 2 have already demonstrated that machine learning can solve biological problems once considered intractable, predicting protein structures with atomic-level accuracy.

The debate mirrors broader tensions in the AI field between techno-optimism and cautious realism. Simons, with his track record of achieving what most consider impossible, clearly falls on the optimistic side.

What This Means for the AI Research Community

Simons' career shift highlights a growing trend: top physicists and mathematicians are gravitating toward AI applications in biology. This talent migration is reshaping how longevity research is conducted, moving it from purely wet-lab experimentation toward computational-first approaches.

For the broader AI community, his work could contribute to advances in several areas:

• Biological foundation models: Large-scale AI models trained on cellular and molecular data
• Quantum-enhanced machine learning: Algorithms that leverage quantum computing principles for biological simulation
• Multi-scale modeling: Connecting quantum-level molecular behavior to organism-level aging processes
• Drug discovery acceleration: AI systems that can identify anti-aging compounds faster than traditional screening

Unlike conventional AI researchers who optimize for benchmark performance, Simons' physics-first perspective could yield fundamentally new approaches to modeling biological systems.

Looking Ahead: Can a Prodigy Solve Aging?

Simons' journey from child prodigy to potential pioneer in AI-driven longevity is remarkable, but the road ahead is extraordinarily challenging. Aging is arguably the most complex biological process known to science, involving genomic instability, telomere attrition, epigenetic alterations, and dozens of other interacting factors.

Still, the tools available today are unprecedented. Modern large language models can parse millions of biomedical papers in seconds. Diffusion models can generate novel molecular structures. Reinforcement learning can optimize drug candidates against multiple biological targets simultaneously.

If Simons maintains his extraordinary pace — completing a bachelor's in 18 months, a PhD in 3 years — he could have his second doctorate by his late teens or early 20s. That would make him one of the youngest dual-PhD holders in history, armed with expertise spanning quantum physics and AI-powered biology.

Whether death truly is just a puzzle waiting to be solved remains an open question. But if anyone has demonstrated the ability to solve puzzles faster than expected, it is Laurent Simons. The AI longevity field just gained one of its most intriguing new voices — and he is barely old enough to drive.